Subscribe
shutterstock_1425318470_photobyphm
Photobyphm / Shutterstock.com
9 December 2019Big PharmaSaman Javed

TAG supports opposition of Sanofi TB drug patents in India

Treatment Action Group ( TAG), a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis (TB), has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sanofi buys Synthorx for $2.5 billion
10 December 2019   Sanofi is to acquire Synthorx, a biotechnology company focused on improving the lives of people suffering from cancer and autoimmune diseases, for $2.5 billion.
Big Pharma
Global Drug Facility adds new TB drug to its catalogue
31 October 2019   The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle